MoodleMoot.hu (Magyar Moodle közösség és konferencia)

Background

Protein Degraders is composed of two functional molecules: one is to bind target protein, and the other is to recruit specific E3 ligase to play the role of ubiquitination-mediated degradation for target protein (see Fig.1). The first Protein Degraders was described by Crews and Deshaies in 2001. In light of various advantages of this technique, it has been applied by a variety of drug discovery to various E3 ligases including pVHL, MDM2, beta-TrCP1, cereblon, and c-IAP1. Protein Degraders had stepped into clinical trial stages for ovarian cancer, prostate cancer. It indicates that Protein Degraders is becoming a promising and attractive therapeutic strategy in pharmaceutical industry.